Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.61 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 13/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.60 |
| ▸ | POLB | P06746 | 10/20 | 0.60 |
| ▸ | BLM | P54132 | 5/20 | 0.60 |
| ▸ | USP2 | O75604 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 10/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22095990 | 0.84 | ITGA4 (0.70) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL12218226 | 0.83 | MEN1 (0.71) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL20718840 | 0.80 | ITGA4 (0.58) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL28364572 | 0.80 | ITGA4 (0.57) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL3755958 | 0.77 | ITGA4 (0.65) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL3755954 | 0.77 | ITGA4 (0.65) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL4605003 | 0.76 | ITGA4 (1.00) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL4605007 | 0.76 | ITGA4 (1.00) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL5991260 | 0.76 | MEN1 (0.62) | ITGA4ITGB7MEN1KMT2APOLB | |
| SCHEMBL14444644 | 0.76 | MEN1 (1.00) | ITGA4ITGB7MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4502193-A1 | STEEL MEMBER AND STEEL SHEET | NIPPON STEEL CORPORATION (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11838761-B2 | Fraud detection based on geolocation data | ALLSTATE INSURANCE COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023190867-A1 | STEEL MEMBER AND STEEL SHEET | 日本製鉄株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20220235134-A1 | ANTI-B7-H3 ANTIBODIES | SINGLE CELL TECHNOLOGY, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| CN-114540330-B | Alkaline protease mutant AprBpM and application thereof | 深圳润康生态环境股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114540330-A | Alkaline protease mutant AprBpM and application thereof | 深圳润康生态环境股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3976660-A1 | ANTI-B7-H3 ANTIBODIES | Single Cell Technology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | ITGA4 3353/4885ITGB7 3128/4885MEN1 63/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | ITGA4 3597/4885ITGB7 3109/4885MEN1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.